Seeing solid accumulation lately. Shareholders will want to lock in big profits so keep eyes peeled for a big move! $CWNM n vitro and in vivo experiments demonstrate the ability of the device to generate nearly-constant and controlled concentrations of drug at the orifice, such as zero-order release kinetics, over a selected period of time. These release kinetics are highly predictable from mathematical modeling. The design also permits controlling kinetics at the beginning and end of the delivery period, allowing fine-tuning of the kinetic profile to match pharmacodynamic expectations (including the magnitude of initial bolus and duration of release).